Drug Therapy Committee
Theodore
Stern, MD, Interin Chair
Dena Alioto, RPh
Kate Barba, RN
Kathryn Beauchamp, RN, MSN
Theodore Benzer, MD
Kathryn Brush, RN
Margaret Clapp, MS, RPh
John Clark, MD
Nicole Devita, RPh
Jessica Dudley, MD
Robert Hallisey, MS, RPh
David Hooper, MD
Michael Langan, MD
Donald Lloyd-Jones, MD
Benjamin
Matthews, MD
Regina Melanson, PharmD, RPh
Kathleen McKibbin, MD
Carl Rosow, MD
Nina Tolkoff-Rubin, MD
Jerry Younger, MD
Editor
Barbara Irby, MS, RPh
Web Design
Ron Imperiali, RPh
Suicide
and Fetal Malformation: Considerations in Prescribing Accutane
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
Volume X, Issue 11,
December, 2000
Alosetron
(Lotronex)-Additional Warnings Issued by the FDA
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
Phenylpropanolamine:Decongestant,
Diet Aid or Stroke in a Bottle?
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
Volume X, Issue 10,
November, 2000
Shedding
Some "Lyte" on Potassium Replacement
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Volume X, Issue 9
October, 2000
Influenza
Chemoprophylaxis
Recommendations of the Drug Therapy Committee
Volume X, Issue 8
September, 2000
Balancing
GI Ulcerations with Renal Dysfunction: The Cox-2 Specific NSAIDs and Acetaminophen
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Clinical
Practice Guidelines - A Needless Intrusion or a Path to Higher Quality
Care?
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Volume X, Issue 7
August, 2000
Cost
of prescription drugs up more than 24.8% since 1996 (Brandeis study):
What can we learn?
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
FDA
to Hold Meetings to Convert Prescription Drugs to OTC
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Negative
Inotropes and Congestive Heart Failure: The Case for the Use of Beta-Blockers
in CHF
Anna Constantinou, Pharm.D., BCPS; Pharmacy Consultant, PCHI and Harold
J. DeMonaco, M.S., Director of Drug Therapy Management
Volume X, Issue 6
June, 2000
Plavix
(clopidogrel) and TTP
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
The
Statins and Inflammation: Class Action or Drug-Specific?
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
Volume X, Issue 5
May, 2000
The
ALLHAT Trial: What's been learned to date?
Anna Constantinou, Pharm.D., BCPS Pharmacy Consultant, PCHI and Harold
J. DeMonaco, M.S., Director of Drug Therapy Management
Volume X, Issue 4
April, 2000
Rezulin
Removed from U.S. Market
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Volume X, Issue 3
March, 2000
Blood
Pressure: Less is More
Update
of the Massachusetts Senior Pharmacy Program(s)
Nicole DeVita RPh, MHP Pharmacy Utilization Consultant, PCHI
What
about Herbal Medicines and Dietary Supplements? Frequently Asked Questions
Posed by Patients
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Volume X, Issue 2
February, 2000
Alosetron,
Serotonin, and the Little Brain
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
HMG
CoA Reductase Inhibitor Prescribing: The MGPO and PCHI
The Drug Therapy Committee
Volume X, Issue 1
January, 2000